STOCK TITAN

Charles Riv Labs Intl Inc - CRL STOCK NEWS

Welcome to our dedicated page for Charles Riv Labs Intl news (Ticker: CRL), a resource for investors and traders seeking the latest updates and insights on Charles Riv Labs Intl stock.

Company Overview

Charles River Labs Intl Inc (CRL) is a globally recognized organization that provides a comprehensive suite of products and services designed to accelerate research and drug development for pharmaceutical, biotechnology, government, and academic institutions. With a strong focus on drug discovery, biotech research, and pharmaceutical testing, CRL is uniquely positioned to support the entire spectrum of early-stage and advanced research initiatives, ensuring that scientific innovations progress efficiently from the discovery phase to safe, scalable manufacturing.

Core Business and Service Offerings

At its core, Charles River Labs specializes in offering tailored support across multiple facets of research and development. The company provides an array of services that include preclinical research, safety assessments, and quality control methodologies. Its expertise spans various functions that are critical to the advancement of new therapies:

  • Drug Discovery and Development: Leveraging state-of-the-art methodologies, the company assists in identifying promising compounds and validating experimental approaches. This accelerates the transition of theoretical research into tangible therapeutic solutions.
  • Preclinical Research Services: By offering comprehensive testing and data generation, CRL plays a vital role in ensuring that experimental treatments meet stringent safety and efficacy standards essential for regulatory approval.
  • Manufacturing Support: The organization supports scalable and safe manufacturing processes, which is critical for transitioning treatments from the lab to commercial production while maintaining high standards of quality assurance.
  • Regulatory and Quality Compliance: With deep expertise in regulatory frameworks, CRL helps clients navigate complex compliance landscapes, ensuring that every step of the drug development process adheres to industry and governmental standards.

Market Position and Industry Context

Charles River Labs stands out by bridging the gap between scientific innovation and practical application within the life sciences sector. The company's services are essential for reducing the time and cost of drug development, which in turn contributes to faster delivery of new therapies to patients in need. Its operations are mapped across global markets, and its service model is built on delivering tailored solutions that address the unique challenges encountered in early-stage research and development.

In a competitive industry characterized by rapid advancements in biotechnology and evolving regulatory standards, CRL’s persistent focus on quality, expertise, and customized client solutions has solidified its market reputation. By integrating advanced analytical techniques with rigorous testing protocols, the company ensures that each project is handled with precision and care, reinforcing its credibility among stakeholders.

Scientific Expertise and Operational Excellence

The scientific rigor and operational excellence of Charles River Labs are evident in its systematic approach to research and innovation. The company harnesses cutting-edge technology and industry-leading practices to deliver a suite of services that not only complement the research lifecycle but also enhance the reliability and reproducibility of scientific outcomes. Its dedicated teams are composed of experts with deep knowledge in various fields, including pharmacology, toxicology, and biotechnology. This multidisciplinary approach enhances the company’s ability to offer comprehensive solutions that address both standard and complex research challenges.

Service Integration and Client-Centric Approach

One of the hallmarks of CRL’s operation is its integrated service model. The company designs its offerings to align with the specific needs of its clients, ensuring that research projects are supported from the initial discovery stage through to the final phases of development. This integration not only streamlines the research process but also minimizes delays associated with disparate service providers. Clients benefit from having a single point of contact for multifaceted research needs, leading to more efficient operations and improved overall outcomes.

Competitive Landscape

Within the competitive environment of pharmaceutical and biotechnological research, Charles River Labs sets itself apart through a combination of extensive industry experience and a robust portfolio of specialized services. Its competitors vary from niche research service providers to larger integrated organizations, yet CRL’s commitment to high standards, precision, and client-focused solutions ensures that it remains a respected collaborator. The company’s emphasis on scientific credibility and operational diligence further solidifies its reputation as a trusted partner in the research community.

Commitment to Quality and Compliance

Ensuring that every product and service meets rigorous quality standards is not just a goal but a core operational mandate at Charles River Labs. The company incorporates stringent quality assurance measures and actively follows best practices in regulatory compliance. This steadfast commitment to quality safeguards client projects from potential setbacks and assures stakeholders of the reliability of the research outcomes generated under its supervision.

Conclusion

Overall, Charles River Labs Intl Inc exemplifies operational excellence in the realm of pharmaceutical and biotechnological research. Its comprehensive service offerings, expert scientific teams, and unwavering commitment to quality and compliance make it an indispensable entity in the drug discovery and development process. By continually enhancing its service model and leveraging its deep industry expertise, CRL remains a critical pillar in advancing the frontiers of medical research and therapeutic development.

Rhea-AI Summary
Charles River Laboratories International, Inc. (CRL) reports fourth-quarter revenue of $1.01 billion, full-year revenue of $4.13 billion, with GAAP earnings per share of $3.62 and non-GAAP earnings per share of $2.46. The company provided 2024 guidance, anticipating a cautious biopharmaceutical demand environment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.3%
Tags
-
Rhea-AI Summary
Charles River Laboratories International, Inc. (NYSE: CRL) has launched the Endosafe® Trillium™ rCR cartridge offering, an animal-free testing solution that enhances testing efficiency and accelerates manufacturing timelines. This innovation builds upon the company's flagship Endosafe® cartridge technology and their recombinant cascade reagent (rCR) to bolster commitments to sustainability and animal welfare.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.94%
Tags
none
-
Rhea-AI Summary
Charles River Laboratories International, Inc. (NYSE: CRL) has appointed Reshema Kemps-Polanco, Executive Vice President and Chief Commercial Officer of Novartis US, to its Board of Directors. With 25 years of experience in the pharmaceutical industry, Ms. Kemps-Polanco will bring valuable insights and knowledge to Charles River's Board. Her extensive experience in leading commercial organizations and her commitment to improving patient access and health outcomes will greatly benefit Charles River's growth strategy. As a member of the Board, she will serve on the Compensation and Strategic Planning and Capital Allocation Committees.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.04%
Tags
management
Rhea-AI Summary
Charles River Laboratories International, Inc. (NYSE: CRL) is set to release its fourth-quarter and full-year 2023 financial results and provide 2024 guidance on February 14th. A conference call will be held at 8:30 a.m. ET on the same day to discuss the information. Investors can listen to a live webcast through the Company's website and access a replay afterward.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.44%
Tags
-
Rhea-AI Summary
Charles River Laboratories International, Inc. (NYSE: CRL) has launched off-the-shelf Rep/Cap plasmid offering to streamline adeno-associated virus (AAV)-based gene therapy programs, reducing manufacturing effort by up to 66%. The ready-to-use plasmid products are produced and released according to batch production records, with CMC guidance and a Certificate of Analysis (COA) to support Investigational New Drug (IND) and Clinical Trial Application (CTA) filing. The launch will take place at Advanced Therapies Week, January 16-19, at the Miami Beach Convention Center.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.39%
Tags
none
-
Rhea-AI Summary
Charles River Laboratories International, Inc. (NYSE: CRL) will present at the 42nd Annual J.P. Morgan Healthcare Conference on January 9th, discussing strategic focus, business developments, and recent trends. A live webcast and replay will be available on the Investor Relations section of the Charles River website at ir.criver.com.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.36%
Tags
conferences
Rhea-AI Summary
Charles River Laboratories International, Inc. (NYSE: CRL) has achieved a significant milestone in their collaboration with Vertex to manufacture CASGEVY™, the world’s first gene-edited therapy targeting severe sickle cell disease. The Memphis facility received regulatory approval from the FDA and HPRA to commercially manufacture an allogeneic cell therapy drug product. This approval enables Charles River to work with Vertex to help bring this groundbreaking treatment to patients suffering from severe sickle cell disease.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.18%
Tags
none
-
Rhea-AI Summary
Charles River Laboratories International, Inc. (NYSE: CRL) has entered into an agreement with CELLphenomics, a biotechnology company using 3D hydrogel technology to advance the understanding of the tumor microenvironment and predict therapeutic efficacy. CELLphenomics’ proprietary 3D tumor model platform, PD3D®, will expand Charles River’s 3D in vitro testing services to optimize oncological approaches for clients. The platform provides reliable, predictive preclinical PD3D models that recapitulate the biological properties of the donor tissue, including key histopathological features and genomic makeup. CELLphenomics’ continuously growing biobank comprises more than 500 complex in vitro models from over 20 tumor entities, offering the world’s largest collection of complex in vitro models of rare and ultra-rare tumors. Leveraging CELLphenomics technology, Charles River will have a novel in vitro option for identifying therapeutics for rare and ultra-rare disease types, with full access to Charles River’s impressive biobank and data.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.05%
Tags
none
-
Rhea-AI Summary
Charles River Laboratories International, Inc. (CRL) partners with Genetic Cures for Kids Inc (GC4K) to produce plasmid DNA for early phase trials of gene therapy for Hereditary Spastic Paraplegia Type 56 (SPG56), a rare neurodegenerative disease. SPG56 affects motor and cognitive functions and currently has no treatment. GC4K aims to develop a gene therapy not only for SPG56 but also as a model for treating other rare genetic diseases. Charles River's eXpDNA™ platform and HQ Plasmid Manufacturing Center of Excellence will support GC4K's mission by providing high-quality plasmid DNA production services.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.27%
Tags
none
Rhea-AI Summary
Charles River Laboratories International, Inc. (CRL) will present at the 6th Annual Evercore ISI HealthCONx Conference on November 29th, discussing strategic focus, business developments, and recent trends. The presentation will be available via live webcast and replay on the Investor Relations section of their website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.12%
Tags
conferences

FAQ

What is the current stock price of Charles Riv Labs Intl (CRL)?

The current stock price of Charles Riv Labs Intl (CRL) is $106.89 as of April 22, 2025.

What is the market cap of Charles Riv Labs Intl (CRL)?

The market cap of Charles Riv Labs Intl (CRL) is approximately 5.2B.

What is the primary focus of Charles River Labs Intl Inc?

The company specializes in providing essential products and research services that accelerate drug discovery, preclinical development, and safe manufacturing of new therapies.

Which industries does CRL primarily serve?

CRL caters to a diverse clientele that includes pharmaceutical companies, biotechnology firms, government agencies, and academic institutions involved in advanced research.

How does Charles River Labs generate revenue?

The company generates revenue by offering a range of research support services, testing solutions, and manufacturing process assistance that are critical to drug development and regulatory compliance.

What sets CRL apart from its competitors?

Charles River Labs distinguishes itself through its integrated service model, deep scientific expertise, stringent quality assurance measures, and a client-centric approach that streamlines research processes.

How does CRL support the drug development process?

The company supports the drug development pipeline by providing preclinical research services, safety assessments, and regulatory guidance, which help expedite the progression from discovery to market realization.

What role does quality assurance play in CRL's operations?

Quality assurance is central to CRL's operations, with rigorous testing protocols and compliance measures ensuring that all research outcomes meet the highest industry standards for safety and effectiveness.

Can CRL assist with both early-stage and advanced research?

Yes, CRL offers services that span from early drug discovery to advanced development stages, ensuring comprehensive support throughout the research and manufacturing lifecycle.

How does the company address regulatory compliance in its services?

Charles River Labs has extensive experience with regulatory frameworks and implements strict quality control and compliance protocols to meet or exceed industry and governmental standards at every step.
Charles Riv Labs Intl Inc

NYSE:CRL

CRL Rankings

CRL Stock Data

5.16B
48.67M
0.94%
106.03%
5.73%
Diagnostics & Research
Services-commercial Physical & Biological Research
Link
United States
WILMINGTON